TransCode Therapeutics, Inc.
RNAZ
$6.97
-$0.235-3.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.51M | -16.76M | -14.93M | -17.91M | -17.06M |
| Total Depreciation and Amortization | 444.40K | 534.80K | 552.10K | 563.40K | 558.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.45M | 3.24M | 1.84M | 2.03M | 1.06M |
| Change in Net Operating Assets | 128.60K | -351.50K | -3.32M | -133.90K | -2.06M |
| Cash from Operations | -12.50M | -13.34M | -15.85M | -15.45M | -17.50M |
| Capital Expenditure | -18.00K | -21.80K | -21.30K | -13.00K | -26.50K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -18.00K | -21.80K | -21.30K | -13.00K | -26.50K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 19.17M | 16.40M | 10.30M | 15.11M | 20.82M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 135.80K | 0.00 |
| Cash from Financing | 19.17M | 16.40M | 10.30M | 15.24M | 20.82M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.66M | 3.04M | -5.58M | -217.80K | 3.29M |